Filtered By:
Source: Cardiovascular Diabetology
Condition: Diabetes

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 57 results found since Jan 2013.

Comparison of oral glucose tolerance test and HbA1c in detection of disorders of glucose metabolism in patients with acute stroke
Diabetes is an increasingly important risk factor for ischemic stroke and worsens stroke prognosis. Yet a large proportion of stroke patients who are eventually diabetic are undiagnosed. Therefore, it is impor...
Source: Cardiovascular Diabetology - December 5, 2020 Category: Cardiology Authors: Karl Matz, Jaakko Tuomilehto, Yvonne Teuschl, Alexandra Dachenhausen and Michael Brainin Tags: Original investigation Source Type: research

The role of blood pressure in risk of ischemic and hemorrhagic stroke in type 1 diabetes
Hypertension is one of the strongest risk factors for stroke in the general population, while systolic blood pressure has been shown to independently increase the risk of stroke in type 1 diabetes. The aim of ...
Source: Cardiovascular Diabetology - July 9, 2019 Category: Cardiology Authors: Stefanie H ägg-Holmberg, Emma H. Dahlström, Carol M. Forsblom, Valma Harjutsalo, Ron Liebkind, Jukka Putaala, Turgut Tatlisumak, Per-Henrik Groop and Lena M. Thorn Tags: Original investigation Source Type: research

GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals
Glucagon-like peptide-1 (GLP-1) treatment has been shown to reduce stroke incidence in diabetes and also to be neuroprotective in experimental stroke models. The prognostic value of endogenous levels of GLP-1 ...
Source: Cardiovascular Diabetology - July 15, 2019 Category: Cardiology Authors: Martin Larsson, Cesare Patrone, Mia von Euler, Jens J. Holst and David Nathanson Tags: Original investigation Source Type: research

Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case –control study
Pioglitazone use is known to be associated with a reduced risk of recurrent stroke in patients with diabetes mellitus (DM) who have a history of stroke. However, it is unclear whether this benefit extends to p...
Source: Cardiovascular Diabetology - July 27, 2021 Category: Cardiology Authors: Junghee Ha, Dong-Woo Choi, Keun You Kim, Chung Mo Nam and Eosu Kim Tags: Original investigation Source Type: research

Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Ischemic stroke patients with diabetes are at high risk for recurrent stroke and cardiovascular complications. Pioglitazone, a type of thiazolidinedione, has been shown to reduce cardiovascular complications i...
Source: Cardiovascular Diabetology - May 5, 2023 Category: Cardiology Authors: Joonsang Yoo, Jimin Jeon, Minyoul Baik and Jinkwon Kim Tags: Research Source Type: research

Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis
To analyze whether medical care is in accordance with guidelines for secondary prevention of myocardial infarction (MI), or stroke in patients with type 2 diabetes from Germany and Austria.
Source: Cardiovascular Diabetology - May 3, 2016 Category: Cardiology Authors: Barbara Bohn, Christof Schöfl, Vincent Zimmer, Michael Hummel, Nikolai Heise, Erhard Siegel, Wolfram Karges, Michaela Riedl and Reinhard W. Holl Source Type: research

Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) ar...
Source: Cardiovascular Diabetology - January 4, 2018 Category: Cardiology Authors: Yan-Rong Li, Sung-Sheng Tsai, Dong-Yi Chen, Szu-Tah Chen, Jui-Hung Sun, Hung-Yu Chang, Miaw-Jene Liou and Tien-Hsing Chen Tags: Original investigation Source Type: research

Pioglitazone and PPAR- γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
Peroxisome proliferator-activated receptor- γ (PPAR-γ) modulating treatment may have cardiovascular benefits in type 2 diabetes mellitus (T2DM) patients after ischemic stroke (IS). However, whether there are ad...
Source: Cardiovascular Diabetology - January 7, 2020 Category: Cardiology Authors: Chi-Hung Liu, Tsong-Hai Lee, Yu-Sheng Lin, Pi-Shan Sung, Yi-Chia Wei and Yan-Rong Li Tags: Original investigation Source Type: research

Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study
Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare. Thus, we...
Source: Cardiovascular Diabetology - June 20, 2020 Category: Cardiology Authors: Yi-Chih Hung, Lu-Ting Chiu, Hung-Yu Huang and Da-Tian Bau Tags: Original investigation Source Type: research

Diet-induced weight loss in obese/diabetic mice normalizes glucose metabolism and promotes functional recovery after stroke
Post-stroke functional recovery is severely impaired by type 2 diabetes (T2D). This is an important clinical problem since T2D is one of the most common diseases. Because weight loss-based strategies have been...
Source: Cardiovascular Diabetology - December 22, 2021 Category: Cardiology Authors: Dimitra Karampatsi, Alexander Zabala, Ulrika Wilhelmsson, Doortje Dekens, Ellen Vercalsteren, Martin Larsson, Thomas Nystr öm, Milos Pekny, Cesare Patrone and Vladimer Darsalia Tags: Original investigation Source Type: research

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this review, we summarize and discus...
Source: Cardiovascular Diabetology - November 15, 2022 Category: Cardiology Authors: Bruno Verg ès, Victor Aboyans, Denis Angoulvant, Pierre Boutouyrie, Bertrand Cariou, Fabien Hyafil, Kamel Mohammedi and Pierre Amarenco Tags: Review Source Type: research

Glyoxal in hyperglycaemic ischemic stroke – a cohort study
Hyperglycaemia is frequent in acute ischemic stroke and denotes a bad prognosis, even in the absence of pre-existing diabetes. However, in clinical trials treatment of elevated glucose levels with insulin did ...
Source: Cardiovascular Diabetology - July 12, 2023 Category: Cardiology Authors: Sina Rhein, Julica Inderhees, Oliver Herrmann, Alaa Othman, Kimberly Begemann, Thomas Fleming, Peter P. Nawroth, Karel D. Klika, Rakad Isa, Inke R. K önig, Georg Royl and Markus Schwaninger Tags: Research Source Type: research

Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study
Conclusions: Our findings suggest that elevated HbA1c levels are an independent risk factor for CVD, especially CHD and ischaemic stroke, and that the addition of HbA1c to the model with traditional risk factors significantly improves the predictive ability of CVD.
Source: Cardiovascular Diabetology - November 7, 2013 Category: Cardiology Authors: Fumie IkedaYasufumi DoiToshiharu NinomiyaYoichiro HirakawaNaoko MukaiJun HataKentaro ShikataDaigo YoshidaTakayuki MatsumotoTakanari KitazonoYutaka Kiyohara Source Type: research

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Background: To evaluate the association of treatment with glucagon-like peptide-1 (GLP-1) receptor agonist exenatide and/or insulin on macrovascular outcomes in patients with type 2 diabetes (T2DM). Methods: We conducted a retrospective longitudinal pharmaco-epidemiological study using large ambulatory care data to evaluate the risks of heart failure (HF), myocardial infarction (MI) and stroke in established T2DM patients who received a first prescription of exenatide twice daily (EBID) or insulin between June 2005 and May 2009, with follow-up data available until December 2012. Three treatment groups were: EBID with oral ...
Source: Cardiovascular Diabetology - January 24, 2015 Category: Cardiology Authors: Sanjoy PaulKerenaftali KleinDavid MaggsJennie Best Source Type: research

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
Conclusions: Analysis of pooled data from 20 clinical trials in patients with T2DM suggests that saxagliptin is not associated with an increased CV risk.
Source: Cardiovascular Diabetology - February 4, 2014 Category: Cardiology Authors: Nayyar IqbalArtist ParkerRobert FrederichMark DonovanBoaz Hirshberg Source Type: research